


# AT A GLANCE: THE MPT R&D PIPELINE

Status of products in development



<sup>1</sup> The dual pill product is going through bioequivalence studies in lieu of clinical trials because the drug components are already approved separately, but not in combination. Therefore, it does not follow the traditional R&D pathway.

<sup>2</sup> This product addresses both HIV and Bacterial vaginosis (BV). BV is not sexually transmitted but can be linked to sexual activity. While BV is not an STI, it has been included here for simplicity.

Adapted from: *The Initiative for MPTs (IMPT) Product Development Database; Treatment Action Group (TAG) 2023 Pipeline Report; MATRIX R&D Landscape Review 2024.*